These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19098165)

  • 1. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.
    Walker MW; Wolinsky TD; Jubian V; Chandrasena G; Zhong H; Huang X; Miller S; Hegde LG; Marsteller DA; Marzabadi MR; Papp M; Overstreet DH; Gerald CP; Craig DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):900-11. PubMed ID: 19098165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence.
    Domin H; Szewczyk B; Pochwat B; Woźniak M; Śmiałowska M
    Psychopharmacology (Berl); 2017 Feb; 234(4):631-645. PubMed ID: 27975125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.
    Packiarajan M; Marzabadi MR; Desai M; Lu Y; Noble SA; Wong WC; Jubian V; Chandrasena G; Wolinsky TD; Zhong H; Walker MW; Wiborg O; Andersen K
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5436-41. PubMed ID: 21782428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
    Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
    Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
    J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
    Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
    J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
    Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats.
    Goyal SN; Kokare DM; Chopde CT; Subhedar NK
    Pharmacol Biochem Behav; 2006 Oct; 85(2):369-77. PubMed ID: 17052748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties.
    Husum H; Bolwig TG; Sánchez C; Mathé AA; Hansen SL
    Epilepsy Behav; 2004 Apr; 5(2):204-15. PubMed ID: 15123022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic psychosocial stress alters NPY system: different effects in rat and tree shrew.
    Zambello E; Fuchs E; Abumaria N; Rygula R; Domenici E; Caberlotto L
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):122-30. PubMed ID: 19846047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor.
    Ishida H; Shirayama Y; Iwata M; Katayama S; Yamamoto A; Kawahara R; Nakagome K
    Hippocampus; 2007; 17(4):271-80. PubMed ID: 17265460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
    Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
    Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety.
    Cippitelli A; Rezvani AH; Robinson JE; Eisenberg L; Levin ED; Bonaventure P; Motley ST; Lovenberg TW; Heilig M; Thorsell A
    Alcohol; 2011 Sep; 45(6):567-76. PubMed ID: 21145691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: involvement of NPY Y1 receptors.
    Goyal SN; Upadhya MA; Kokare DM; Bhisikar SM; Subhedar NK
    Brain Res; 2009 Apr; 1266():45-53. PubMed ID: 19254701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze.
    Bacchi F; Mathé AA; Jiménez P; Stasi L; Arban R; Gerrard P; Caberlotto L
    Peptides; 2006 Dec; 27(12):3202-7. PubMed ID: 16959374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.